Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors

作者：Song Hui; Li Chia Wei; Labaff Adam M; Lim Seung Oe; Li Long Yuan; Kan Shu Fen; Chen Yue; Zhang Kai; Lang Jingyu; Xie Xiaoming; Wang Yan; Huo Long Fei; Hsu Sheng Chieh; Chen Xiaomin; Zhao Yingming; Hung Mien Chie^*

来源：Biochemical and Biophysical Research Communications, 2011, 404(1): 68-73.

DOI：10.1016/j.bbrc.2010.11.064

• EGFR
• CBP
• Acetylation
• Phosphorylation
• SAHA

Alteration of epidermal growth factor receptor (EGFR) is involved in various human cancers and has been intensively investigated. A plethora of evidence demonstrates that posttranslational modifications of EGFR play a pivotal role in controlling its function and metabolism. Here, we show that EGFR can be acetylated by CREB binding protein (CBP) acetyltransferase. Interestingly, EGFR acetylation affects its tyrosine phosphorylation, which may contribute to cancer cell resistance to histone deacetylase inhibitors (HDACIs). Since there is an increasing interest in using HDACIs to treat various cancers in the clinic, our current study provides insights and rationale for selecting effective therapeutic regimen. Consistent with the previous reports, we also show that HDACI combined with EGFR inhibitors achieves better therapeutic outcomes and provides a molecular rationale for the enhanced effect of combination therapy. Our results unveil a critical role of EGFR acetylation that regulates EGFR function, which may have an important clinical implication. Published by Elsevier Inc.

• 出版日期2011-1-7
• 单位中国医科大学